

SFDPH Responds to Hepatitis C: Strategy and Program Update, 2015-2020



Presented by:

**Katie Burk, MPH
Viral Hepatitis Coordinator
Community Health Equity & Promotion Branch
Population Health Division**




Presentation Outline

- 2015 HCV programmatic goal review
- SFHP updates
- Updates re: awareness campaigns, testing, and SFHN treatment
- Priority populations strategies
- COVID-related HCV challenges
- Lessons learned
- Next steps for 2020 and beyond

Bay Area Reporter article on the End Hep C SF Research Symposium, Sept 2019



SFDPH's 5 HCV Programmatic Goals, 2015




Necessary conditions for success

- ✓ Integrated service models
- ✓ Partnerships within DPH and with external organizations

End Hep C SF Initiative, Launched 2016

VISION

End Hep C SF envisions a San Francisco where hepatitis C is no longer a public health threat and HCV-related health inequities have been eliminated.



www.endhepcsf.org



San Francisco Health Plan Update: Cost and Progress

- Cost per HCV treatment has significantly decreased
 - List price for Mavyret \$26,400 as of 8/17
- 37% of the SFHP members with known HCV were treated (approximately 2000 people)


Treatment Regimens	Mbrs	%
MAVYRET 100-40 MG TABLET	719	35%
HARVONI 90-400 MG TABLET 12-24 wk	409	20%
HARVONI GENERIC	2	0%
EPCLUSA 400 MG-100 MG TABLET	367	18%
EPCLUSA GENERIC	160	8%
ZEPATIER 30-100 MG TABLET	196	10%
VOSEVI 400-100 MG TABLET	40	2%
Daklinza + Sovaldi 12 wks	62	3%
SOVALDI 400 MG TABLET 12-24 wks	46	2%
VIEKIRA PAK 12 wk	14	1%
Olysio + Sovaldi 12-24 wks	14	1%
TECHNIVIE DOSE PACK	1	0%
TOTAL	2030	

*Harvoni (ledipasvir 90mg/sofosbuvir 400mg)

*Olysio (asunaprevir 150mg)


*Sovaldi (sofosbuvir 400mg)

*Viekira (ombitasvir 12.5mg/paritaprevir 75mg/ritonavir 50mg)





Community Awareness

We can't treat Hep C if we don't know we have it.




**There is new hope for people with Hep C
Come visit us to talk about the new cure**

San Francisco Aids Foundation
Syringe Access Services
117 6th Street
San Francisco, CA 94103
sfaf@endhepcsf.org
For more info, visit www.endhepcsf.com



“New Treatments Have Changed the Game” social marketing campaign, 2015-2016



End Hep C SF Video Series, 2019



Tales from the Community: Continuing Care at UCSF Viral Hepatitis Center

JENNIFER PRICE | AUGUST 21, 2020 | UNCATEGORIZED

As a hepatologist at UCSF, my clinical practice includes treating people living with hepatitis C (HCV) as well as managing patients with complications of viral...

[READ MORE →](#)



Tales from the Community: Adapting to COVID-19 at GLIDE

AMY RODRIGUEZ | AUGUST 17, 2020 | VOICES

The role we play in HCV elimination here at Glide is mostly comprised of heavily testing folks in the community for Hepatitis C as well...


[READ MORE →](#)

End Hep C SF Blog Series, 2020

Community-Based HCV Testing

339% increase in community-based HCV testing between Q1 2016 and Q4 2019, followed by a steep drop off in testing numbers due to COVID restrictions

Community-Based HCV Rapid Antibody Testing 2016-2020*



San Francisco Health Network

Primary Care-Based HCV Treatment Initiative

Three components of the capacity-building HCV treatment initiative for primary care physicians in the San Francisco Health Network, as of February 2016:

- In-person training
- eReferral consultation services
- Individualized clinic TA

Pre- and Post-Intervention Analysis

	Pre-intervention (16 months)		Post-intervention (23 months)		% increase
	Total #	#/month	Total #	#/month	
Total Patients Treated*	143	8.9	435	18.9	112%
Total Clinics represented among treated	5	n/a	12	n/a	140%

Facente SN, Burk K, Eagen K, Mara KS, Smith AA, Lynch CS. New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care. Infectious Disease Clinics of North America. 2018 Jun;32(2):313-322. doi: 10.1016/j.idc.2018.02.012.

Priority Population: Individuals Co-infected with HIV & HCV

16,000 PLWH in San Francisco

DPH

NON-DPH

3,831 (24%) HIV+ Active San Francisco Health Network (SFHN) Patients

Kaiser and Other Private Providers

Out of Care

216 (32%)
Currently
Coinfected

468 (68%)
Successfully
Treated

Unknown

Microelimination Strategies:

- Enable data to care
- Develop programs for care settings, within and beyond the safety net
- Invest in elimination for communities with highest barriers to care and treatment

Priority Population: Criminal Justice-Involved Individuals

2017 Jail Health HCV Treatment Study	
# Treated	99
# Achieved SVR-12	77
2019 Jail Health HCV Testing Data	
# HCV Tests	1851
# New HCV cases	55
Antibody Reactivity Rate	approx. 3%

- Ongoing challenges securing funds to pay for HCV treatment for incarcerated individuals
- Modest amount of funds allocated in budget for continuing HCV treatment for incarcerated individuals

Priority Population: People Who Inject Drugs and/or Experience Homelessness


Treatment Site	# Tx Starts	# Achieved SVR-12 ¹	Program Initiated
OTOP, (UCSF)	223	180	August 2016
Syringe Exchange (SFAF)	230 ²	155	August 2016
SF County Jail	99	77	March 2017
Street Medicine	81	36	May 2016
DeLiver van	16	12	August 2019

¹SVR-12 as a marker for success discounts dozens of additional patients who have completed treatment and been cured

²approximation



COVID-related HCV Challenges



- Diminished capacity of work force due to COVID activation
 - Surveillance upgrades and overhauls on pause
 - Clinical leadership preoccupied with COVID trials
- Safety protocols necessitate reduced capacity for programs
- Social isolation of target population associated with exacerbated substance use, mental health challenges
- HCV RNA labs delayed due to labs being overwhelmed with COVID testing

“COVID has obviously slowed things down, but we are getting our groove back!”
Dr. Jennifer Price, UCSF DeLiver Van

Lessons Learned

- Be willing to adjust and change course
- Don't give up on big systems changes
- Focus on leadership development efforts and understand HCV leadership can come in many forms
- Create multiple thresholds for participation
- Prioritize inclusion of people most impacted by HCV, and get creative about how to involve them

**Sharing equipment
spreads Hep C**
Come get sterile stuff




There is new hope for people with Hep C
Come visit us to talk about the new cure

Glide Harm Reduction Program - 5th floor
330 Ellis Street (between Taylor & Jones)
San Francisco, CA 94102
(415) 674-5188 / hepc@glide.org
For more info, visit www.endhepcsf.org



Next Steps: 2020 and Beyond





San Francisco Department of Public Health

Thank you

Katie Burk

Viral Hepatitis Coordinator

katie.burk@sfdph.org

Currently activated for COVID-19



POPULATION HEALTH DIVISION
SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

Acknowledgements

Rachel Grinstein

Jennifer Price, MD

Jessica Naugle, NP

Lisa Ghotbi, PharmD

Andrew Reynolds

Annie Luetkemeyer, MD

Joanne Kay

Emily Raganold

David Leiva

Shelley Facente, MPH, PhDc